Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mobocertinib PK in Severe Renal Impairment
NCT04056455Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2020
- Primary completion
- Apr 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of mobocertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to Infinity and 7 more. Started Mar 2020; status: completed.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04056455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056455.